Guerbet’s research team designed Dotarem® (gadoterate meglumine) with a unique profile, providing the highest molecular stability to minimize the risk of gadolinium release.1
Dotarem’s unique profile features:
Important Safety Information2
WARNING: NEPHROGENIC FIBROSIS (NSF)
Indications and Usage
Warnings and Precautions
Use in Specific Populations
You are encouraged to report negative side effects of prescription drugs to the FDA.Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see the full Prescribing Information, including the patient Medication Guide, for additional important safety information.
(Please see Prescribing Information)
* Log Ktherm = absolute thermodynamic stability constant
Dotarem (gadoterate meglumine) Injection, 0.5 mmol/mL
Pharmacy Bulk Package: NOT FOR DIRECT INFUSION
For U.S. Reimbursement Information, please see attached information for Hospital Outpatient settings and Freestanding/Independent Diagnostic Testing Facility (IDTF) settings.
For further assistance, please contact DOTAREM Reimbursement Support at 1-855-368-2736, Monday–Friday, 7 am–7 pm ET.
Dotarem® is a registered trademark of Guerbet LLC or its affiliates, and is available by prescription only.
Legal Copyright 2018 Guerbet
* Reimbursement information provided is for illustrative purposes only and does not constitute legal advice. Information provided is gathered from third party sources and is subject to change without notice due to frequently changing laws, rules and regulations. Guerbet makes no guarantee that the use of this information will prevent differences of opinion or disputes with Medicare or other third party payers as to the correct form of billing or the amount that will be paid to providers of service. The provider of service has the responsibility to determine medical necessity and to submit appropriate codes and charges for care provided. Please contact your local payers, reimbursement specialists and/or legal counsel for interpretation of coding, coverage, and payment policies. Guerbet does not promote the use of its products outside FDA-approved labeling.